Barry Wohl

Chief Business Officer

Barry has diverse operating and strategic planning experience in both the medical device and biopharma sectors. Previously, he was Senior Director of Alliance Management at Macrolide Pharmaceuticals, a venture-backed startup developing novel antibiotics in the macrolide class of molecules. Prior to Macrolide, he held an Entrepreneur-in-residence role as a Blavatnik Fellow at Harvard Business School, where he co-founded and was Chief Business Officer of Symbal Therapeutics, a company developing a novel antibiotic for multi drug-resistant infections. The company partnered its lead preclinical-stage asset in 2016. Prior to that, he worked with global biotech firms of all sizes and development stages as a strategy consultant with IMS Consulting Group and concurrently in a sell-side transaction advisory role with IMS Health Capital. He began his career with Medtronic, where he worked as a product design engineer and later as a global clinical trial lead on a variety of vascular and cardiac rhythm implantable devices, several of which went on to capture significant market share. He holds a BS in biomedical engineering, magna cum laude, from Columbia, an MS in mechanical engineering from Stanford and an MBA from Harvard Business School.